The Food and Drug Administration has approved Invega Hafyera™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting atypical antipsychotic that is administered as a gluteal intramuscular injection by a health care professional. Prior to initiating treatment with Invega Hafyera, patients must have been adequately treated…
A comparative list of psychotropic medications with their mood disorder indications (bipolar disorder, major depressive disorder, treatment resistant depression, premenstrual dysphoric disorder, and others).
Expert panel recommendations on the screening and step-wise diagnosis of neurogenic orthostatic hypotension (nOH).
This week we have news of the FDA requesting a change to statin prescribing labels, a new vaccine for streptococcus pneumoniae, a new plaque psoriasis cream, a stem cell therapy gets fast tracked as a possible Parkinson disease treatment, and there’s a new treatment approved for Progressive Familial Intrahepatic Cholestasis.
Drugs in the Pipeline
DA01 is an investigational pluripotent stem cell-derived dopaminergic neuron therapy designed to replace the midbrian dopaminergic neurons lost in Parkinson disease.
The system works with Medtronic’s Percept™ PC Neurostimulator.
Parkinson's drug treatment chart categorized by pharmacological class.